DESTINY-Breast03 Phase 3 Study Results
TDD of QLQ-C30 Emotional Functioning
100
80
60
60
60
Time to definitive deterioration, %
40
40
T
20
20
+ Censor
T-DXd (n = 261)
T-DM1 (n=263)
Ο
DESTINY-Breast03
Daiichi-Sankyo
Median (95% CI) TDD, months
16.4 (14.1-19.9) HR (95% CI): 0.69 (0.53-0.89)
10.5 (9.0-13.8) P value: 0.0049
0
1
2
3
4 5
Patients at risk:
CO
6
7
8
9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28
Time, months
20 19 17 12 10 7 3 10
T-DXD 261 241 220212 209 195 189 178 166 155 144 132 116 100 89 74 57 39 32 25
T-DM1 263 243 208 187 177 155 130 117 102 80 71 59 43 32 26 22 18 15 10 7 7 6 4 4 1 1 0
EORTC, European Organization for Research and Treatment of Cancer; HR, hazard ratio; QLQ-C30, Quality of Life Core 30 questionnaire; TDD, time to definitive
deterioration; T-DM1, trastuzumab emtansine; T-DXd, trastuzumab deruxtecan.
P values are not adjusted for multiple testing. TDD is defined as a >10-point change from baseline.
ESMO BC 2022 #1630 Oral
46
40View entire presentation